A2A Pharmaceuticals, Inc. has bought BMEA on 2 days since Sep 2021

A2A Pharmaceuticals, Inc. is a privately held biotechnology company based in New York City that designs computationally optimized small‑molecule therapeutics for the treatment of cancer and antibiotic‑resistant bacterial infections.( Founded in 2016, the company leverages proprietary computational and AI‑driven drug‑design platforms to accelerate the development of novel drug candidates for life‑threatening diseases, including triple‑negative breast, ovarian, endometrial cancers, bacterial infections, and muscular dystrophy.( A2A’s lead clinical asset, AO‑252, is described as a first‑in‑class protein–protein interaction inhibitor of TACC3, currently in Phase 1 dose‑escalation studies in oncology.(

A2A Pharmaceuticals operates with a small team (approximately 2–10 employees) and focuses on cancer therapeutics, drug design, and antibiotics as its core specialties.( The company is led by founder Edward Painter, MBA, who serves as Chairman and CIO and brings about 30 years of finance and biotech capital‑markets experience from roles at firms such as Goldman Sachs, Credit Suisse, UBS, Oppenheimer & Co., Kidder Peabody, and Salomon Brothers.( As a corporate insider, A2A Pharmaceuticals, Inc. is reported as a 10% owner of Biomea Fusion, Inc. (BMEA), holding approximately 3.5 million shares and having executed multiple Form 4‑reported transactions in BMEA over the past several years.(

Written by Perplexity from public sources.